MX2020010075A - Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. - Google Patents
Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.Info
- Publication number
- MX2020010075A MX2020010075A MX2020010075A MX2020010075A MX2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A MX 2020010075 A MX2020010075 A MX 2020010075A
- Authority
- MX
- Mexico
- Prior art keywords
- lysin
- polypeptide constructs
- polynucleotides encoding
- lysins
- isolated polynucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01017—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente descripción se dirige a construcciones de lisina-polipéptidos AMP, polipéptidos de lisina aislados y composiciones farmacéuticas que comprenden los polipéptidos aislados y/o construcciones de lisina-polipéptidos AMP. También se proporcionan en este documento métodos para usar las construcciones de lisina-polipéptidos AMP, polipéptidos de lisina aislados y composiciones farmacéuticas, incluidos métodos para tratar una infección bacteriana de un órgano o tejido en el que está presente un tensioactivo pulmonar o infecciones bacterianas Gramnegativas que están asociadas con una biopelícula. Además, los polinucleótidos aislados que codifican para las construcciones de lisina polipéptido AMP y los polipéptidos de lisina aislados se describen en este documento.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862650235P | 2018-03-29 | 2018-03-29 | |
US201862721969P | 2018-08-23 | 2018-08-23 | |
US201862722793P | 2018-08-24 | 2018-08-24 | |
PCT/US2019/024912 WO2019191633A2 (en) | 2018-03-29 | 2019-03-29 | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010075A true MX2020010075A (es) | 2021-01-08 |
Family
ID=68060804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010075A MX2020010075A (es) | 2018-03-29 | 2019-03-29 | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11773140B2 (es) |
EP (1) | EP3775192A4 (es) |
JP (1) | JP2021519083A (es) |
KR (1) | KR20200136980A (es) |
CN (1) | CN112368376A (es) |
AU (1) | AU2019245369A1 (es) |
BR (1) | BR112020019484A2 (es) |
CA (1) | CA3095484A1 (es) |
IL (1) | IL277119A (es) |
MX (1) | MX2020010075A (es) |
WO (1) | WO2019191633A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2953446A1 (en) * | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
AU2019245333A1 (en) * | 2018-03-29 | 2020-10-29 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
US10988520B2 (en) * | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
AU2019245369A1 (en) | 2018-03-29 | 2020-10-29 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
CA3136126A1 (en) * | 2019-04-05 | 2020-10-08 | Contrafect Corporation | Lysins and derivatives thereof with bactericidal activity against pseudomonas aeruginosa, in the presence of human serum |
MX2021015563A (es) * | 2019-07-05 | 2022-03-17 | Contrafect Corp | Polipéptidos anti-microbianos, derivados de bacteriófago, y sus usos contra bacterias gramnegativas y acidorresistentes. |
EP4058468A4 (en) * | 2019-11-14 | 2024-04-10 | Contrafect Corp | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF |
WO2021211303A1 (en) * | 2020-04-14 | 2021-10-21 | Contrafect Corporation | Antiviral, bacteriophage-derived polypeptides and their use against viruses |
US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
IL307148A (en) * | 2021-03-26 | 2023-11-01 | Contrafect Corp | Amorinin, lysins and antimicrobial lysine-peptide structures are active against gram-negative bacteria |
WO2022236088A1 (en) * | 2021-05-06 | 2022-11-10 | Bioharmony Therapeutics Inc. | Lysin polypeptide compositions and methods of use |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ555039A (en) | 2004-11-12 | 2009-09-25 | Novozymes As | Polypeptides having antimicrobial activity and polynucleotides encoding same |
EP2444105A4 (en) | 2009-06-16 | 2013-08-21 | Univ Tokai | GRAM NEGATIVE ANTI-BACTERIAL AGENT |
JP6034188B2 (ja) * | 2009-06-26 | 2016-11-30 | ライサンド アクツィエンゲゼルシャフト | 抗微生物剤 |
BRPI1015192A2 (pt) * | 2009-06-26 | 2019-09-17 | Katholieke Univ Leuven K U Leuven R&D | agentes antimicrobianos |
AU2010288559B8 (en) | 2009-08-24 | 2015-08-13 | Katholieke Universiteit Leuven, K.U. Leuven R&D | New endolysin OBPgpLYS |
EP2468856A1 (en) | 2010-12-23 | 2012-06-27 | Lysando Aktiengesellschaft | Antimicrobial Agents |
EP2699689A4 (en) | 2011-04-21 | 2014-12-17 | Univ Utrecht Holding Bv | LYSINES OF BACTERIOPHAGES OF STREPTOCOCCUS FOR THE TREATMENT OF GRAM POSITIVE BACTERIA IN PET ANIMALS AND IN LIVESTOCK |
EP2993181A1 (en) | 2011-04-27 | 2016-03-09 | Lysando AG | New antimicrobial agents |
US9518252B2 (en) | 2011-05-26 | 2016-12-13 | Dsm Ip Assets B.V. | Listeria bacteriophage P825 and uses thereof |
US8790639B2 (en) | 2012-03-28 | 2014-07-29 | The United States Of America, As Represented By The Secretary Of Agriculture | Enhanced antimicrobial lytic activity of a chimeric Ply187 endolysin |
KR101391332B1 (ko) | 2012-05-18 | 2014-05-07 | 연세대학교 산학협력단 | 카바페넴 제제에 내성을 보이는 아시네토박터 속의 균을 용균하는 박테리오파아지 |
WO2014001571A1 (en) | 2012-06-29 | 2014-01-03 | Lysando Ag | Composition for use in mycobacteria diagnosis |
CN102861324A (zh) | 2012-10-17 | 2013-01-09 | 重庆市第三人民医院 | 治疗耐碳青霉烯类鲍曼不动杆菌感染的生物试剂 |
CA2953446A1 (en) | 2014-06-26 | 2015-12-30 | The Rockefeller University | Acinetobacter lysins |
RU2728682C2 (ru) * | 2015-09-17 | 2020-07-31 | Контрафект Корпорейшн | Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики |
KR102000120B1 (ko) | 2017-01-26 | 2019-07-15 | 주식회사 코미팜 | 이유 자돈의 대장균증을 예방하기 위한 재조합 p22 라이소자임 - pmap36 융합 단백질을 이용한 장내독소형 대장균(etec) 고스트 백신 조성물 |
BR112020011433A2 (pt) | 2017-12-12 | 2020-12-01 | Contrafect Corporation | identificação de lisinas e seus derivados com atividade bacteriana contra pseudomonas aeruginosa |
AU2019245369A1 (en) | 2018-03-29 | 2020-10-29 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
US10988520B2 (en) | 2018-03-29 | 2021-04-27 | Contrafect Corporation | Lysin-antimicrobial peptide (AMP) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
AU2019245333A1 (en) | 2018-03-29 | 2020-10-29 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
EP3840771A4 (en) * | 2018-08-23 | 2023-04-19 | Contrafect Corporation | ANTIMICROBIAL LYSINE-PEPTIDE (AMP) POLYPEPTIDE CONSTRUCTIONS, LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEM AND THEIR USES |
US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
-
2019
- 2019-03-29 AU AU2019245369A patent/AU2019245369A1/en active Pending
- 2019-03-29 CA CA3095484A patent/CA3095484A1/en active Pending
- 2019-03-29 EP EP19776817.9A patent/EP3775192A4/en active Pending
- 2019-03-29 CN CN201980036007.XA patent/CN112368376A/zh active Pending
- 2019-03-29 JP JP2020551860A patent/JP2021519083A/ja active Pending
- 2019-03-29 KR KR1020207031049A patent/KR20200136980A/ko not_active Application Discontinuation
- 2019-03-29 WO PCT/US2019/024912 patent/WO2019191633A2/en active Application Filing
- 2019-03-29 MX MX2020010075A patent/MX2020010075A/es unknown
- 2019-03-29 US US17/041,691 patent/US11773140B2/en active Active
- 2019-03-29 BR BR112020019484-0A patent/BR112020019484A2/pt unknown
-
2020
- 2020-09-03 IL IL277119A patent/IL277119A/en unknown
-
2023
- 2023-08-18 US US18/452,038 patent/US20240018192A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11773140B2 (en) | 2023-10-03 |
KR20200136980A (ko) | 2020-12-08 |
EP3775192A4 (en) | 2022-06-01 |
IL277119A (en) | 2020-10-29 |
CN112368376A (zh) | 2021-02-12 |
EP3775192A2 (en) | 2021-02-17 |
US20240018192A1 (en) | 2024-01-18 |
BR112020019484A2 (pt) | 2021-01-12 |
JP2021519083A (ja) | 2021-08-10 |
AU2019245369A1 (en) | 2020-10-29 |
RU2020129467A (ru) | 2022-05-04 |
WO2019191633A2 (en) | 2019-10-03 |
WO2019191633A3 (en) | 2019-11-07 |
US20210047374A1 (en) | 2021-02-18 |
CA3095484A1 (en) | 2019-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010075A (es) | Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos. | |
EA202190906A1 (ru) | Рекомбинантное получение препаратов пептидов коллагена и их применение | |
BR112017007816A2 (pt) | composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas | |
MX2020011257A (es) | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. | |
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
EA201891589A1 (ru) | Условно активные гетеродимерные полипептиды и способы их применения | |
SA518390954B1 (ar) | لقاحات علاجية لفيروس الورم الحليمي البشري 18 | |
EA201792651A1 (ru) | Аденовирусные полинуклеотиды и полипептиды | |
TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
MX2021003475A (es) | Metodos de purificacion de proteinas. | |
AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
IL277120A (en) | Antimicrobial Peptide Lysine Polypeptide Templates, Lysines, Isolated Polynucleotides Encoding Them and Their Uses | |
EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
MX2021000263A (es) | Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma. | |
EP4096696A4 (en) | POLYPEPTIDE CONSTRUCTS CONTAINING LYSINE ANTIMICROBIAL PEPTIDE (AMP), LYSINE, ISOLATED POLYNUCLEOTIDES ENCODING THEREWITH AND USES THEREOF | |
MX2022011973A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
EA201792362A8 (ru) | Композиции и способы для лечения целиакии спру | |
PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
MX2021001129A (es) | Metodo de purificacion de antigenos. | |
MX365560B (es) | Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes. | |
MX2018000023A (es) | Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina. | |
EP4058468A4 (en) | POLYPEPTIDE CONSTRUCTIONS OF ANTIMICROBIAL PEPTIDE LYSINE (AMP), LYSINES, ISOLATED POLYNUCLEOTIDES ENCODING THEREFOR AND USES THEREOF | |
PH12020551618A1 (en) | Erenumab compositions and uses thereof | |
MX2021008005A (es) | Bibliotecas de peptidos y metodos de uso de las mismas. | |
MX2019012525A (es) | Proteinas de citomegalovirus modificadas y complejos estabilizados. |